ERBB2 and breast carcinoma: The purpose of this study is to develop a nomogram model for MMP genomic risk assessment in patients with hormone receptor positive, HER2 negative, and minimal axillary burden (N0-1) breast cancer by using widely used clinicopathological factors for predicting breast cancer outcomes in a subset of patients subjected to the MMP test to enable prompt screening of patients with extremely high chance of receiving either low or high.genomic risk results.